Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > THTX for retail investors

<< Previous

Bullboard Posts

Next >>

Comment by houbahopon Feb 08, 2021 1:05pm

111 Views

Post# 32502137

RE:RE:RE:RE:RE:RE:THTX for retail investors

Reading the posts from various members here, it seems the people in upper management making the business culture at Thera have not changed their modus operandi in recent years. Shareholders reactions to how they feel towards the decisions taken by the Board of Directors is very similar to those many years ago.

The future for Thera shareholders is most probably a continuation pattern from the past.

I see nothing different today compare to 20 years ago.

In these situations, experiences from the past might prevent you from repeating stupid mistakes.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario